Piqray FDA Approval History
Last updated by Judith Stewart, BPharm on July 1, 2019.
FDA Approved: Yes (First approved May 24, 2019)
Brand name: Piqray
Generic name: alpelisib
Dosage form: Tablets
Company: Novartis Pharmaceuticals Corporation
Treatment for: Breast Cancer
Piqray (alpelisib) is a kinase inhibitor indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR positive, HER2-negative, PIK3CA-mutated breast cancer.
Development timeline for Piqray
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.